BRCA Mutation in Prostate Cancer

Both genes normally help repair broken DNA. In prostate cancer, though, BRCA2 carries far more weight than BRCA1.

Pooled data put the increased prostate cancer risk at 5.24-fold for BRCA2 carriers, with a confidence interval of 4.63 to 5.49. For BRCA1 the figure is 1.57, with a range of 1.30 to 1.91. For cancer diagnosed before age 65, the BRCA2 figure climbs to 6.37-fold.

About 2% of men with early-onset prostate cancer carry a germline BRCA2 change.

BRCA2 does not just raise the odds of getting prostate cancer. It shifts what kind of cancer shows up.

The relative risk of aggressive prostate cancer in BRCA2 carriers is 6.08, with a range of 3.44 to 10.8. One prospective study found BRCA2 carriers with a Gleason score above 7 had a standardized incidence ratio of 5.07, ranging from 3.20 to 8.02. A meta-analysis found 71.1% of BRCA2 carriers had a Gleason score of 7 or higher, against 36.3% of BRCA1 carriers.

Survival tracks the same way. For BRCA2 carriers, the hazard ratio for cancer-specific survival is 2.63, ranging from 2.00 to 3.47. For overall survival it is 2.21, ranging from 1.64 to 2.99.

Those are population figures, not a forecast for one person. They explain why a BRCA2 result usually pushes a team toward treating rather than watching.

Two different tests can both find a BRCA change, and they mean different things.

A germline test looks at DNA you were born with, usually from blood or saliva. A change there is in every cell, and it can be passed to children.

A somatic test looks at tumor tissue. A change found only there arose in the cancer itself and is not inherited.

For drug eligibility the distinction often does not matter. The approved prostate indications cover germline and somatic changes alike. For your family, it matters enormously.

The class of drugs is PARP inhibitors. They block a second DNA repair pathway. A cancer cell that has already lost BRCA repair and then loses PARP repair has no way to fix its DNA, and it dies.

Olaparib is approved for adults with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer, after progression on enzalutamide or abiraterone. Castration-resistant means the cancer is growing despite testosterone being suppressed.

The HRR gene list on the label runs well past BRCA: ATM, BRCA1, BRCA2, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L. Either tumor or blood testing can establish it. The dose is 300 mg by mouth twice daily.

Olaparib also has a separate indication in combination with abiraterone and a corticosteroid, for BRCA-mutated metastatic castration-resistant prostate cancer. That regimen uses abiraterone 1000 mg daily with prednisone or prednisolone 5 mg twice daily.

Every figure in this section comes from the labels. Your own prescription is what to follow, and the steroid that goes with abiraterone must never be stopped on your own.

Rucaparib received regular FDA approval on December 17, 2025 for adults with a deleterious BRCA mutation, germline or somatic, in metastatic castration-resistant prostate cancer previously treated with androgen receptor-directed therapy. The dose is 600 mg by mouth twice daily, given as two 300 mg tablets, for a total of 1,200 mg a day.

The supporting trial was TRITON3. It enrolled 405 men, 302 with a BRCA mutation and 103 with an ATM mutation, randomly assigned 2 to 1 to rucaparib or to the physician's choice of enzalutamide, abiraterone, or docetaxel. Among the BRCA group, median radiographic progression-free survival was 11.2 months with rucaparib against 6.4 months with the comparator. The hazard ratio was 0.50, with a 95% confidence interval of 0.36 to 0.69 and a p value below 0.0001.

Both drugs require patient selection with an FDA-approved companion diagnostic, meaning a specific validated test rather than any genetic panel.

For men at average risk, prostate cancer screening generally starts somewhere between ages 45 and 75.

For men carrying a germline pathogenic variant that raises prostate cancer risk, screening is recommended starting at age 40. That is a five-year head start at minimum, and it applies to male relatives who test positive even if they never develop symptoms.

BRCA testing is rarely ordered alone. Two other findings are worth recognizing.

HOXB13, specifically the G84E variant, raises prostate cancer risk 3-fold to 5-fold overall and about 10-fold for early-onset disease. Lifetime risk reaches roughly 60% by age 80. Notably, there is no clear link between G84E and aggressive disease, so the finding changes screening more than it changes treatment.

Mismatch repair genes, the Lynch syndrome genes, matter too. In one study, the cumulative risk of a prostate cancer diagnosis by age 70 was 30% in carriers, against 8% in the general population. Carriers were diagnosed younger, at an average of 60.4 years versus 66.6 years, and showed more Gleason 8 to 10 disease.

ATM and CHEK2 also appear on standard testing panels, and ATM appears on the olaparib label.

A germline BRCA2 finding does not stay inside urology.

For you, it raises the question of other BRCA2-associated cancers and of ongoing surveillance beyond the prostate. For your children, each has a 50% chance of inheriting the same variant, and for daughters that carries breast and ovarian cancer implications. For siblings and parents, it converts a vague family history into a single testable variant.

This is the argument for involving a genetic counselor rather than reading the report alone. The people who need this information are often not in the room.

• Was the test germline, somatic, or both, and on which sample
• Which specific gene and which variant, in the report's own notation
• Was the variant called pathogenic, likely pathogenic, or a variant of uncertain significance
• Was it an FDA-approved companion diagnostic, since drug access can hinge on that
• Has a genetic counselor been involved, and have relatives been notified
• Does this change the treatment being proposed right now, or the timing of it

A variant of uncertain significance is not a positive result. It means the lab found a change and cannot yet classify it. Those get reclassified over time, so ask when the lab will re-review it.

Two things drive this list: a PARP inhibitor if you are taking one, and the fact that BRCA2-linked prostate cancer more often spreads to bone.

• Call 911 or go to an emergency department if you have sudden weakness in your legs, numbness around the groin or inner thighs, or new trouble controlling your bladder or bowels. Pressure on the spinal cord is a time-critical emergency, and how long the weakness has been there affects whether walking is preserved.
• Call your care team the same day if back pain is constant, worse at night, or worse when you cough or strain. That is the most common warning of the same problem, and it usually comes before any weakness. Call the same day for a temperature of 100.4°F (38°C) or higher, or chills.
• Call your care team within a day or two if you are on olaparib or rucaparib and notice easy bruising or bleeding, blood in your urine or stool, pale skin, breathlessness, or tiredness and weakness that keep deepening. Those drugs are watched for effects on the bone marrow.

https://www.cancer.gov/types/prostate/hp/prostate-genetics-pdq https://www.ncbi.nlm.nih.gov/books/NBK557604/ https://medlineplus.gov/druginfo/meds/a617002.html https://www.cancer.gov/about-cancer/treatment/side-effects/infection https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-rucaparib-metastatic-castration-resistant-prostate-cancer https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications